<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330963</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00788</org_study_id>
    <nct_id>NCT04330963</nct_id>
  </id_info>
  <brief_title>Swiss Primary Hypersomnolence and Narcolepsy Cohort Study</brief_title>
  <acronym>SPHYNCS</acronym>
  <official_title>Swiss Primary Hypersomnolence and Narcolepsy Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinik Barmelweid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentrum für Schlafmedizin Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Regionale di Lugano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zurzach Care Klinik für Schlafmedizin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (SPHYNCS) is a cohort study on&#xD;
      disease presentation and long-term course with an exploratory approach to detect biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An exploratory prospective, national, multi-center cohort study on clinical,&#xD;
      electrophysiological and biological biomarkers of disease presentation and course.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Proportion of study subjects with diagnosis of Narcolepsy type 1 (NT1) at follow up</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of study subjects with final diagnosis other than NT1 but within the group of CDH at follow up</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with autoreactive T-cell clones in NT1 and some Narcolepsy borderland (NBL) subjects but not in controls</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preptidomic profile of NT1 and NBL in comparison to controls</measure>
    <time_frame>36 months</time_frame>
    <description>Mass spectrometry based peptidomics of cerebrospinal fluid (CSF) for the identification of Hypocretin and approximately 6000 other neuropeptides in 10 to 20 samples for each group to be analyzed. In collaboration with the group of Prof. Matthias Mann, Max Planck Institute of Biochemistry, Planegg, Germany</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome of NT1 and NBL in comparison to controls</measure>
    <time_frame>36 months</time_frame>
    <description>16S based analysis of the gut microbiome based on stool samples from all participants (where available). In collaboration with the group of Prof. Andrew Macpherson, University of Bern</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Narcolepsy</condition>
  <condition>Idiopathic Hypersomnia</condition>
  <condition>Hypersomnolence Disorder</condition>
  <arm_group>
    <arm_group_label>Hypersomnolence group</arm_group_label>
    <description>All patients referred to the outpatient clinic/sleep center for investigation due to complaints for excessive daytime sleepiness (EDS) and/or Hypersomnia (H) and/or suspected central disorder of hypersomnolence (CDH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>SDB controls</arm_group_label>
    <description>Patients with EDS and diagnosis of severe sleep related breathing disorder (SBD) significantly improving with therapy.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood cerebrospinal fluid (CSF) Stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The project population consists of subjects, who were referred to the outpatient clinic /&#xD;
        sleep center of one of the study sites for further investigation, due to complaints of EDS&#xD;
        and / or H and / or suspected Central disorders of hypersomnolence (CDH), fulfilling&#xD;
        inclusion / exclusion criteria and a control population as well as healthy controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Study participants:&#xD;
&#xD;
          -  Subjective complaints of Excessive daytime sleepiness (EDS) and/or Hypersomnia (H) as&#xD;
             defined above&#xD;
&#xD;
          -  EDS and/or H present daily or almost daily for at least 1 month prior to the&#xD;
             consultation&#xD;
&#xD;
          -  Ability and consent to undergo electrophysiological routine assessment&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Healthy controls:&#xD;
&#xD;
          -  Age and gender matched healthy subjects&#xD;
&#xD;
          -  Including blood related relatives of study participants&#xD;
&#xD;
          -  Ability and consent to undergo electrophysiological routine assessment&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Controls with Sleep disordered breathing (SDB):&#xD;
&#xD;
          -  Subjective complaints of EDS with Epworth Sleepiness Scale (ESS) &gt; 10 (adults) and/or&#xD;
             H due to SDB: Presence of clinically significant and untreated obstructive sleep apnea&#xD;
             (OSA) as determined by the investigator with an apnea-hypopnea-index &gt;30/h&#xD;
&#xD;
          -  Multiple sleep-latency test (MSLT) mean sleep latency ≤ 8min&#xD;
&#xD;
          -  Subjective and objective improvement of EDS and/or H within 3 months after treatment&#xD;
             with&#xD;
&#xD;
          -  Positive airway pressure (PAP) therapy with documented&#xD;
&#xD;
               -  Reduction of apnea-hypopnea index below &lt;10/h&#xD;
&#xD;
               -  Reduction of ESS by ≥ 25%&#xD;
&#xD;
               -  MSLT mean Sleep Latency &gt; 12min&#xD;
&#xD;
          -  Ability and consent to undergo electrophysiological routine assessment&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Study participants and controls:&#xD;
&#xD;
          -  SDB for study participants and healthy controls: Presence of clinically significant&#xD;
             and untreated obstructive sleep apnea (OSA) or central sleep apnea (CSA) as determined&#xD;
             by the investigator or documented previously; or documentation of one of the&#xD;
             following:&#xD;
&#xD;
               -  Apnea index (AI) &gt; 10 if on OSA treatment or untreated; or&#xD;
&#xD;
               -  Clinically significant hypoventilation; or&#xD;
&#xD;
               -  Noncompliance with primary OSA therapy&#xD;
&#xD;
               -  except if NT1 has been diagnosed including decreased or missing cerebrospinal&#xD;
                  fluid (CSF) hypocretin&#xD;
&#xD;
          -  SDB for control population with SDB:&#xD;
&#xD;
               -  Central Sleep Apnea (CSA)&#xD;
&#xD;
               -  Noncompliance with primary OSA therapy and/or&#xD;
&#xD;
               -  No reported improvement of EDS and/or H within 3 months of positive airway&#xD;
                  pressure (PAP) treatment&#xD;
&#xD;
          -  The following disorders/conditions that on clinical grounds are considered to be the&#xD;
             cause of EDS / H&#xD;
&#xD;
               -  Other sleep disorders (e.g. Restless legs syndrome (RLS) with periodic leg&#xD;
                  movement syndrome (PLMS), sleepwalking, clear-cut circadian disorder)&#xD;
&#xD;
               -  Other neurological disorders (e.g. stroke, multiple sclerosis, parkinsonism,&#xD;
                  severe traumatic brain injury)&#xD;
&#xD;
               -  (Auto-)immune and systemic disorders (such as Hashimoto Thyroiditis, Chron's&#xD;
                  Disease, ulcerous colitis, Diabetes mellitus type I, Systemic lupus&#xD;
                  erythematosus)&#xD;
&#xD;
               -  Malignancy (except: Status in Remission for at least &gt; 10 years)&#xD;
&#xD;
               -  Instable psychiatric disorder (e.g. acute psychotic, acute suicidal, episode of&#xD;
                  major depression requiring in-hospital treatment, active substance abuse)&#xD;
&#xD;
               -  Active infectious disease at screening&#xD;
&#xD;
               -  Permanent medications / drugs&#xD;
&#xD;
          -  Chronic infectious diseases (such as Hepatitis B/C, HIV)&#xD;
&#xD;
          -  Chronic use of antibiotics&#xD;
&#xD;
          -  Recent use (&lt; 8 weeks) of immune-modulating drugs&#xD;
&#xD;
        Healthy controls additional:&#xD;
&#xD;
          -  Subjective complaints of EDS and / or H&#xD;
&#xD;
          -  ESS &gt; 10&#xD;
&#xD;
          -  Polysomnography (PSG) with AI &gt; 10/h and / or PLMS Index &gt; 30/h&#xD;
&#xD;
          -  MSLT mean Sleep Latency &lt; 12 min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio L Bassetti, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Insel Gruppe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudio L Bassetti, Prof.</last_name>
    <phone>+41 31 63 2 30 66</phone>
    <phone_ext>+41316323066</phone_ext>
    <email>Claudio.Bassetti@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Warncke, PhD</last_name>
    <phone>+41 31 66 4 07 99</phone>
    <email>jan.warncke@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Claudio L Bassetti</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio L Bassetti, Prof</last_name>
      <phone>+41316323066</phone>
      <phone_ext>+41316323066</phone_ext>
      <email>Claudio.Bassetti@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Jan Warncke, PhD</last_name>
      <phone>+41 31 664 07 99</phone>
      <email>jan.warncke@insel.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U, Khatami R, Koning F, Kornum BR, Lammers GJ, Liblau RS, Luppi PH, Mayer G, Pollmächer T, Sakurai T, Sallusto F, Scammell TE, Tafti M, Dauvilliers Y. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019 Sep;15(9):519-539. doi: 10.1038/s41582-019-0226-9. Epub 2019 Jul 19. Review.</citation>
    <PMID>31324898</PMID>
  </reference>
  <reference>
    <citation>Latorre D, Kallweit U, Armentani E, Foglierini M, Mele F, Cassotta A, Jovic S, Jarrossay D, Mathis J, Zellini F, Becher B, Lanzavecchia A, Khatami R, Manconi M, Tafti M, Bassetti CL, Sallusto F. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018 Oct;562(7725):63-68. doi: 10.1038/s41586-018-0540-1. Epub 2018 Sep 19.</citation>
    <PMID>30232458</PMID>
  </reference>
  <reference>
    <citation>Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain. 1997 Aug;120 ( Pt 8):1423-35.</citation>
    <PMID>9278632</PMID>
  </reference>
  <reference>
    <citation>Dietmann A, Wenz E, van der Meer J, Ringli M, Warncke JD, Edwards E, Schmidt MH, Bernasconi CA, Nirkko A, Strub M, Miano S, Manconi M, Acker J, von Manitius S, Baumann CR, Valko PO, Yilmaz B, Brunner AD, Tzovara A, Zhang Z, Largiadèr CR, Tafti M, Latorre D, Sallusto F, Khatami R, Bassetti CLA. The Swiss Primary Hypersomnolence and Narcolepsy Cohort study (SPHYNCS): Study protocol for a prospective, multicentre cohort observational study. J Sleep Res. 2021 Oct;30(5):e13296. doi: 10.1111/jsr.13296. Epub 2021 Apr 4.</citation>
    <PMID>33813771</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Idiopathic Hypersomnia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

